- Trials with a EudraCT protocol (19)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
19 result(s) found for: Periodic Fever Syndrome.
Displaying page 1 of 1.
EudraCT Number: 2013-004291-35 | Sponsor Protocol Number: CACZ885N2301 | Start Date*: 2014-05-16 | |||||||||||||||||||||
Sponsor Name:Novartis Farma SpA | |||||||||||||||||||||||
Full Title: A randomized, double-blind, placebo controlled study of canakinumab in patients with Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), with subsequent randomized withdrawal/ dosing frequency redu... | |||||||||||||||||||||||
Medical condition: Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) ES (Completed) IE (Completed) DE (Completed) BE (Completed) HU (Completed) NL (Completed) GR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001678-40 | Sponsor Protocol Number: CACZ885N2301E2 | Start Date*: 2017-05-15 | |||||||||||
Sponsor Name:Novartis pharma AG | |||||||||||||
Full Title: An extension study of safety of canakinumab in Japanese patients with periodic fever syndromes | |||||||||||||
Medical condition: Three disease of periodic fever syndromes, TNF receptor Associated Periodic Syndrome (TRAPS), Hyper IgDSyndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020061-24 | Sponsor Protocol Number: CACZ885D2203 | Start Date*: 2010-08-24 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 5-month follow-up and long-term treatment period in patients with active recurrent or chronic TNF-recepto... | |||||||||||||
Medical condition: TNF-receptor associated periodic syndrome (TRAPS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005154-57 | Sponsor Protocol Number: CACZ885D2307E1 | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003490-15 | Sponsor Protocol Number: CACZ885D2308 | Start Date*: 2016-04-14 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharmaceuticals | ||||||||||||||||||||||||||||
Full Title: An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated P... | ||||||||||||||||||||||||||||
Medical condition: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Muckle-Wells Syndrome Neonatal Onset Multisystem Inflammatory Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016859-22 | Sponsor Protocol Number: CACZ885D2307 | Start Date*: 2013-02-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A one-year open-label, multicenter trial to assess efficacy, safety and tolerability of canakinumab (ACZ885) and the efficacy and safety of childhood vaccinations in patients aged 4 years or younge... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) GB (Completed) BE (Completed) Outside EU/EEA IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001393-34 | Sponsor Protocol Number: MNILCAPS001 | Start Date*: 2014-04-14 | |||||||||||
Sponsor Name:UZ Leuven | |||||||||||||
Full Title: Ilaris® (canakinumab) efficacy and safety in CAPS patients without confirmed mutation on exon 3 of gene CIAS1 and young (<2yrs) CAPS patients with severe neurological (CINCA) phenotype. | |||||||||||||
Medical condition: Cryopyrin-Associated Periodic Syndromes | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024156-28 | Sponsor Protocol Number: CACZ885DDE03T | Start Date*: 2011-05-16 | |||||||||||
Sponsor Name:Charité - University Hospital of Berlin | |||||||||||||
Full Title: A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome | |||||||||||||
Medical condition: Schnitzler syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004290-97 | Sponsor Protocol Number: ACCILTRA1 | Start Date*: 2008-12-19 |
Sponsor Name:Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy | ||
Full Title: A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzle... | ||
Medical condition: The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-004367-22 | Sponsor Protocol Number: CACZ885D2306 | Start Date*: 2008-05-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated periodi... | |||||||||||||
Medical condition: The following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) BE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000489-40 | Sponsor Protocol Number: IZD174-002 | Start Date*: 2020-09-22 | |||||||||||
Sponsor Name:Inflazome (Australia) Pty Ltd. | |||||||||||||
Full Title: A Multi-Centre, Randomised, Open-Label, Phase IIb Study to Evaluate the Safety, Tolerability and Efficacy of IZD174 in Patients with Cryopyrin Associated Periodic Syndromes | |||||||||||||
Medical condition: Cryopyrin-associated periodic syndrome (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002715-41 | Sponsor Protocol Number: P130934 | Start Date*: 2015-08-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: KAWAKINRA study, "A phase IIa multicenter trial to assess the efficacy and safety of Anakinra in patients with intraveinous immunoglobulin-resistant Kawasaki disease" | |||||||||||||
Medical condition: Anakinra treatment is expected to reduce the early and long term mortality of patients with Kawasaki Disease (KD), by a rapid and sustained effect on vascular inflammation | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001849-13 | Sponsor Protocol Number: 2013/cardio3 | Start Date*: 2013-07-09 |
Sponsor Name:ASLTO2-Maria Vittoria Hospital Cardiology | ||
Full Title: AnakInRa Treatment of Recurrent Idiopathic Pericarditis | ||
Medical condition: idiopathic recurrent pericarditis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005528-12 | Sponsor Protocol Number: VIB7734.P2.S1 | Start Date*: 2021-08-17 | |||||||||||
Sponsor Name:Viela Bio, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001951-42 | Sponsor Protocol Number: ReCOVery-SIRIO | Start Date*: 2020-05-08 | |||||||||||
Sponsor Name:Uniwersytet Mikołaja Kopernika w Toruniu | |||||||||||||
Full Title: Amiodarone or Verapamil in COVID-19 hospitalized patients with symptoms: Randomized clinical trial | |||||||||||||
Medical condition: Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003369-20 | Sponsor Protocol Number: CT-P59_3.2 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R... | |||||||||||||
Medical condition: SARS CoV 2 infection in outpatients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005707-32 | Sponsor Protocol Number: MK-7655-003 | Start Date*: 2012-07-13 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients wit... | ||||||||||||||||||
Medical condition: Patients with Complicated Urinary Tract Infection at least 18 years of age, with a diagnosis of either complicated cUTI or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) GR (Completed) LV (Completed) BG (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001264-28 | Sponsor Protocol Number: P2-IMU-838-COV | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Immunic AG | |||||||||||||
Full Title: A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator’s Choice of Standard of Ca... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) RO (Completed) GR (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000974-25 | Sponsor Protocol Number: 61186372NSC2005 | Start Date*: 2023-04-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Evaluation of Amivantamab Infusion Related Reaction Mitigation | |||||||||||||
Medical condition: EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.